Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction…

Overview of attention for article published in Urologic Oncology, June 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

twitter: 16 X users

guideline: 2 clinical guideline sources

Readers on

mendeley: 22 Mendeley

So far, Altmetric has seen 22 X posts from 16 X users, with an upper bound of 42,513 followers.

Lewis J. Thomas IV, MD, contributed to a comparative study of the efficacy of a BCG alternative treatment in patients with recurrent non-muscle invasive bladder cancer: https://t.co/V24IxH68Vm https://t.co/UHDldZKdJ2

#WashUUrology's Lewis Thomas IV, MD, joined colleagues from around the U.S. and Canada to compare the efficacy of BCG therapeutic alternatives in patients with recurrent non-muscle invasive bladder cancer: https://t.co/NVD6N8ds6r https://t.co/U87O9s8Oah

Check out this paper - Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG - https://t.co/QEJfXH…

RT @WashU_Uro: #WashUUrology's Lewis Thomas IV, MD, collaborated with national researchers to note immunotherapy alternatives must be consi…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 18 additional X posts.